الفهرس 
H EPATITIS C V IRUSOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Background: Hepatitis C virus HCV infection is one of the main causes of chronic liver disease worldwide, Egypt has the highest national-level HCV prevalence in the world, Sofosbuvir/Daclatasvir (SOF/DAC) regimen widely used to treat HCV infection in Egypt.
Aim of the study: to assess changes in renal indices during and after HCV treatment in chronic hepatitis C patients treated with sofosbuvir/daclatasvir, with or without ribavirin with normal baseline creatinine
Methods :This study was a real life data analysis which recruited a number of ”509” patients who received (SOF/DAC) regimen for 12 weeks with or without ribavirin in New Cairo viral Hepatitis Treatment Center, one of the NCCVH specialized centers. According to Supreme Council and NCCVH Hepatitis C updated Treatment Protocol included patients received either:
- Sofosbuvir (400mg) + Daclatasvir (60mg) for 12weeks or
- Sofosbuvir (400mg) + Daclatasvir (60mg) + Ribavirin for 12weeks.
All data for chronic HCV patients who treated with sofosbuvir /daclatasvir, with or without ribavirin with normal baseline creatinine and achieved SVR,were compared to assess changes in renal indices during and after HCV treatment
Results: At the end of treatment, the estimated glomerular filtration rate (eGFR) level was significantly decreased and the serum creatinine( Scr) levels were significantly increased compared with baseline levels (eGFR: 91.63 ± 26.41 vs 85.71 ± 24.86 ,P01 < 0.001; Scr: .87 ± .20 vs.92 ± .22, P01 < 0.001and no significant improvements were observed at 24 w post-treatment (eGFR: 89.65 ± 26.14vs 91.63 ± 26.41 ,P02 = 0.029; Scr: .89 ± .24. vs 87 ± .20, P02 = 0.020. Considering the difference in liver conditions, changes in renal function indices were compared between cirrhotic patients and non-cirrhotic patients. At the end of treatment, cirrhotic patients and non-cirrhotic patients had decreased eGFR levels and increased Scr levels at 24 w post-treatment, the eGFR and Scr levels were significantly improved in non-cirrhotic patients, while no obvious improvements were observed in cirrhotic patients.
Conclusion: Although DAAs are highly effective and well tolerated, at the end of treatment we found that: The eGFR level was significantly decreased and the Scr levels were significantly increased compared with baseline levels and no significant improvements were observed at 24 w post-treatment.Both Cirrhotic patients and non-cirrhotic patients had decreased eGFR levels and increased Scr levels at 24 w post-treatment but the eGFR and Scr levels were significantly improved in non-cirrhotic patients , while no obvious improvements were observed in cirrhotic patients.